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Letters to the Editor
Histopathological data
Sir
We read with interest the recent paper by Pichon MF et al (1996).
We first noted that the following histopathological data had
been used in this study: tumour classification, tumour grading,
maximum tumour diameter and axillary lymph node status. These
data were derived from the records of the pathological examina-
tion of2257 tumorectomies or mastectomies. We then noticed that
the histology slides had apparently not been reviewed by a panel
of pathologists. Surely, this has become an indispensable way of
ensuring a minimum ofquality control in any multicentre study of
this type. Being further aware that the authors ofthis paper did not
include a single pathologist, we were dismayed by the complete
lack of any reference to the several pathologists who had obvi-
ously contributed to this monumental series.
We wish to strongly urge editors and referees of international
oncology journals, when reviewing multicentre studies primarily
based on histopathological data, to ensure that such papers are
adequately reviewed by a panel of pathologists and that the
identity and affiliation of contributing or panelist pathologists are
clearly indicated.
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Histopathological data-
reply
Sir
The aim of our study, using the data of medical records obtained
under the conditions of current medical practice, was to evaluate
the relationship between the results of quantitative measurements
of hormone receptors in primary tumours and the occurrence of
events during the monitoring of breast cancers. In French Cancer
Centres, the diagnosis, treatment and monitoring ofbreast cancers
is carried out by multidisciplinary teams made up of specialists
who all contribute to the elaboration of the medical records
common to the Institution.
This paper did not purport to focus on histological correlations,
which merely represent four out ofnine criteria studied.
Consequently, we saw no case for a specific post-review of
histological data, as the main criteria of this study, oestradiol and
progesterone receptors, were permanently subject to quality
control. This is common standard practice for all laboratories
engaged in steroid receptor assays.
Furthermore, no recent similar studies include post-verification
of histological data (Spyratos et al, 1992; Pujol et al, 1994;
Romain et al, 1995, 1996).
In so far as no further work is required from any other speciality
outside the present team, there is no justification for certain
specialists rather than others in the list ofauthors. In addition, the
majority of this series of patients' records has already been the
object ofprevious publications to which pathologists were associ-
ated (more than 25 papers in all).
MF Pichon
On behalfof
The Group de Biopathologie Tissulaire
et Moleculaire
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BRCAI polymorphisms
Sir
Determining the clinical significance of germline alterations in
BRCAJ has serious implications for predicative assessment of
breast and ovarian cancer risk. While the majority ofalterations in
BRCAJ are frameshift or nonsense mutations that are likely to
damage gene function severely, determining the status of intronic
sequence variants or of rare sequence variants that result in
missense alterations is more difficult and conflicting interpreta-
tions of such variants have been published. We report here on two
such variants which we believe can now be classified as non-
pathological rare sequence variants.
Perhaps the most controversial of these variants is a 12-
nucleotide duplication 48 base pairs downstream of the 3'
boundary ofexon 20. Although this is in aregion unlikely to affect
RNA splicing, it was tentatively classified as a mutation by
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